[Study of the calmodulin-dependent regulation of calcium adenosine triphosphatase of erythrocyte membranes in patients with ischemic heart disease].

The inhibitor calmodulin (R 24571) was examined for effects on the activity of red blood cell Ca-ATPases in patients with coronary heart disease during the treatment with nitrates, beta-blockers and calcium antagonists. The maximum activity of Ca-ATPase was measured in the erythrocytes perforated with saponine in the presence of endogenous regulators at a concentration of Ca2+ of 3-5 microM. Patients with high and low Ca-ATPase activity were identified. In the control group R24571 failed to affect Ca-ATPase activity. In patients, the calmodulin inhibitor caused both Ca-ATPase activation and inhibition. The effects of R 24571 correlated with the severity of the patients' condition. In effective therapy, the action of the calmodulin inhibitor became lower on Ca-ATPase activity. It was concluded that there was Ca-ATPase regulation imbalance in patients with coronary heart diseases.